 Christina Finlayson
Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 26 | 2017 | 2456 | 0.900 |
Why?
| | Carcinoma, Ductal, Breast | 5 | 2017 | 88 | 0.460 |
Why?
| | Mastectomy, Segmental | 5 | 2017 | 108 | 0.360 |
Why?
| | Receptors, Estrogen | 7 | 2012 | 457 | 0.310 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2008 | 118 | 0.290 |
Why?
| | Lymph Nodes | 3 | 2007 | 502 | 0.280 |
Why?
| | Thoracic Vertebrae | 1 | 2007 | 79 | 0.260 |
Why?
| | Prostheses and Implants | 1 | 2007 | 141 | 0.240 |
Why?
| | Mammography | 1 | 2007 | 166 | 0.240 |
Why?
| | Receptors, Progesterone | 4 | 2012 | 356 | 0.200 |
Why?
| | src Homology Domains | 1 | 2003 | 35 | 0.200 |
Why?
| | Mastectomy | 3 | 2007 | 162 | 0.190 |
Why?
| | Estrogens | 3 | 2012 | 380 | 0.180 |
Why?
| | Preoperative Care | 2 | 2001 | 380 | 0.180 |
Why?
| | Mammaplasty | 1 | 2001 | 104 | 0.160 |
Why?
| | Patients | 1 | 2001 | 182 | 0.160 |
Why?
| | Phytotherapy | 1 | 2000 | 74 | 0.150 |
Why?
| | Vitamin E | 1 | 2000 | 121 | 0.150 |
Why?
| | Postoperative Hemorrhage | 1 | 2000 | 104 | 0.150 |
Why?
| | Counseling | 1 | 2001 | 408 | 0.140 |
Why?
| | Neoplasm Staging | 8 | 2010 | 1465 | 0.140 |
Why?
| | Tamoxifen | 5 | 2012 | 217 | 0.130 |
Why?
| | Reoperation | 2 | 2017 | 631 | 0.130 |
Why?
| | Pelvic Exenteration | 1 | 1996 | 12 | 0.120 |
Why?
| | Pelvic Neoplasms | 1 | 1996 | 24 | 0.120 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 99 | 0.120 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 100 | 0.110 |
Why?
| | Neoadjuvant Therapy | 3 | 2010 | 463 | 0.110 |
Why?
| | Carcinoma, Lobular | 2 | 2017 | 56 | 0.110 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 226 | 0.110 |
Why?
| | Hodgkin Disease | 1 | 2016 | 171 | 0.110 |
Why?
| | Antineoplastic Agents, Hormonal | 4 | 2012 | 194 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2010 | 1462 | 0.100 |
Why?
| | Insulin | 1 | 2003 | 2507 | 0.090 |
Why?
| | Signal Transduction | 3 | 2012 | 5233 | 0.090 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 41 | 0.090 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2008 | 222 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1358 | 0.090 |
Why?
| | Breast | 2 | 2003 | 159 | 0.080 |
Why?
| | Carcinoma in Situ | 1 | 2011 | 44 | 0.080 |
Why?
| | Axilla | 2 | 2007 | 51 | 0.080 |
Why?
| | Female | 23 | 2017 | 78376 | 0.080 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1563 | 0.080 |
Why?
| | Keratin-5 | 1 | 2010 | 48 | 0.080 |
Why?
| | Radiotherapy | 2 | 2008 | 206 | 0.080 |
Why?
| | BRCA2 Protein | 1 | 2009 | 67 | 0.070 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 63 | 0.070 |
Why?
| | Thrombophilia | 1 | 2009 | 88 | 0.070 |
Why?
| | Estrogen Receptor alpha | 1 | 2010 | 161 | 0.070 |
Why?
| | Humans | 30 | 2017 | 144957 | 0.070 |
Why?
| | Middle Aged | 14 | 2017 | 35928 | 0.070 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 75 | 0.070 |
Why?
| | Palliative Care | 1 | 1996 | 1008 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2010 | 883 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 245 | 0.060 |
Why?
| | Breast Cyst | 1 | 2006 | 2 | 0.060 |
Why?
| | Cyst Fluid | 1 | 2006 | 20 | 0.060 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 149 | 0.060 |
Why?
| | Carcinoma, Papillary | 1 | 2007 | 79 | 0.060 |
Why?
| | Sternum | 1 | 2006 | 27 | 0.060 |
Why?
| | Biomarkers, Tumor | 2 | 2010 | 1322 | 0.060 |
Why?
| | Phosphoproteins | 2 | 2008 | 346 | 0.060 |
Why?
| | Melatonin | 1 | 2006 | 163 | 0.060 |
Why?
| | Carcinoma, Ductal | 1 | 2005 | 10 | 0.060 |
Why?
| | Ki-67 Antigen | 1 | 2005 | 117 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 826 | 0.050 |
Why?
| | Combined Modality Therapy | 4 | 2008 | 1268 | 0.050 |
Why?
| | Adult | 12 | 2017 | 40506 | 0.050 |
Why?
| | Retroviridae Proteins, Oncogenic | 1 | 2003 | 10 | 0.050 |
Why?
| | Oncogene Protein v-akt | 1 | 2003 | 22 | 0.050 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2003 | 55 | 0.050 |
Why?
| | Bone Neoplasms | 1 | 2006 | 256 | 0.050 |
Why?
| | Receptor, Insulin | 1 | 2003 | 94 | 0.050 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2003 | 76 | 0.050 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 484 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 253 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2009 | 783 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 557 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 292 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2017 | 17101 | 0.050 |
Why?
| | Urachus | 1 | 2002 | 1 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2007 | 853 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2007 | 1141 | 0.040 |
Why?
| | Mastectomy, Radical | 1 | 2000 | 4 | 0.040 |
Why?
| | Nurse Anesthetists | 1 | 2000 | 7 | 0.040 |
Why?
| | Aged | 6 | 2017 | 25947 | 0.040 |
Why?
| | Prospective Studies | 2 | 2003 | 7997 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2738 | 0.040 |
Why?
| | Phosphorylation | 1 | 2003 | 1733 | 0.040 |
Why?
| | Gynecomastia | 1 | 1998 | 6 | 0.040 |
Why?
| | Immunohistochemistry | 3 | 2008 | 1718 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2012 | 521 | 0.040 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2002 | 259 | 0.040 |
Why?
| | Endocrine System Diseases | 1 | 1998 | 35 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2000 | 268 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2012 | 758 | 0.030 |
Why?
| | Survival Rate | 2 | 2008 | 2092 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 51 | 0.030 |
Why?
| | Apoptosis | 2 | 2010 | 2430 | 0.030 |
Why?
| | Gene Expression Profiling | 3 | 2008 | 1786 | 0.030 |
Why?
| | Ultrasonography | 1 | 2000 | 770 | 0.030 |
Why?
| | Consensus | 1 | 2017 | 489 | 0.030 |
Why?
| | Estradiol | 2 | 2010 | 533 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 335 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2010 | 8279 | 0.030 |
Why?
| | Lymph Node Excision | 2 | 2009 | 173 | 0.030 |
Why?
| | Decision Making | 1 | 2001 | 980 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2017 | 589 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2000 | 931 | 0.020 |
Why?
| | CD24 Antigen | 1 | 2012 | 18 | 0.020 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 29 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 102 | 0.020 |
Why?
| | Patient Selection | 1 | 1996 | 719 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 369 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 322 | 0.020 |
Why?
| | Colorado | 2 | 2017 | 4564 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1996 | 1054 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2011 | 183 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 919 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2010 | 3550 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 610 | 0.020 |
Why?
| | Mass Screening | 1 | 1998 | 1348 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2010 | 63 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 110 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 320 | 0.020 |
Why?
| | Databases, Protein | 1 | 2010 | 90 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 143 | 0.020 |
Why?
| | Prognosis | 2 | 2009 | 4293 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 82 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 930 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 355 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 14 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 136 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 18 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2009 | 266 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 187 | 0.020 |
Why?
| | Databases as Topic | 1 | 2008 | 71 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 17 | 0.020 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 17 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 412 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 36 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 509 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 92 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 76 | 0.020 |
Why?
| | Perimenopause | 1 | 2008 | 66 | 0.020 |
Why?
| | Mastectomy, Modified Radical | 1 | 2007 | 6 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2008 | 323 | 0.020 |
Why?
| | SEER Program | 1 | 2008 | 224 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2008 | 334 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1187 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2007 | 36 | 0.020 |
Why?
| | Doxorubicin | 1 | 2009 | 397 | 0.020 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 61 | 0.020 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2006 | 42 | 0.020 |
Why?
| | Mice, Nude | 1 | 2008 | 688 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 2006 | 171 | 0.010 |
Why?
| | Transcriptome | 1 | 2012 | 1046 | 0.010 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 343 | 0.010 |
Why?
| | Neoplasms | 1 | 2000 | 2884 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2007 | 444 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2006 | 479 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 737 | 0.010 |
Why?
| | Patient Care Planning | 1 | 2005 | 170 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 421 | 0.010 |
Why?
| | Quality of Life | 1 | 1996 | 3192 | 0.010 |
Why?
| | Antineoplastic Agents | 2 | 2008 | 2197 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1495 | 0.010 |
Why?
| | Proteomics | 1 | 2010 | 1195 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2499 | 0.010 |
Why?
| | Mice | 2 | 2012 | 18365 | 0.010 |
Why?
| | Postmenopause | 1 | 2005 | 391 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 998 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 11695 | 0.010 |
Why?
| | Umbilicus | 1 | 2002 | 17 | 0.010 |
Why?
| | Phenotype | 1 | 2010 | 3164 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 2002 | 47 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3415 | 0.010 |
Why?
| | Biopsy | 1 | 2005 | 1077 | 0.010 |
Why?
| | Age Factors | 1 | 2008 | 3335 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1888 | 0.010 |
Why?
| | Hospitals, Private | 1 | 1999 | 12 | 0.010 |
Why?
| | Hospitals, County | 1 | 1999 | 11 | 0.010 |
Why?
| | United States | 1 | 2017 | 15988 | 0.010 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2000 | 163 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1958 | 0.010 |
Why?
| | Hospitals, University | 1 | 1999 | 176 | 0.010 |
Why?
| | Male | 4 | 2012 | 72406 | 0.010 |
Why?
| | Leydig Cell Tumor | 1 | 1998 | 8 | 0.010 |
Why?
| | Animals | 2 | 2012 | 38109 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 6434 | 0.010 |
Why?
| | Testicular Neoplasms | 1 | 1998 | 113 | 0.010 |
Why?
| | NF-kappa B | 1 | 2000 | 662 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 7191 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 1998 | 636 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2000 | 1217 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 1999 | 1327 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1999 | 780 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 10792 | 0.010 |
Why?
| | Models, Biological | 1 | 2000 | 1822 | 0.010 |
Why?
| | Adolescent | 1 | 1998 | 22453 | 0.000 |
Why?
|
|
Finlayson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|